CVS Health (NYSE: CVS) reported Q3 EPS of $1.50, $0.01 better than the analyst estimate of $1.49. Revenue for the quarter came in at $46.2 billion versus the consensus estimate of $46.17 billion.

• Narrowed and raised the mid-point of the range for full year GAAP diluted EPS from continuing operations to $4.98 to $5.02 from $4.92 to $5.02
• Narrowed and raised the mid-point of the range for full year Adjusted EPS to $5.87 to $5.91 from $5.83 to $5.93
• Provided fourth quarter GAAP diluted EPS from continuing operations of $1.75 to $1.79
• Provided fourth quarter Adjusted EPS of $1.88 to $1.92
• Confirmed full year cash flow from operations of $7.7 to $8.6 billion; free cash flow of $6.0 to $6.4 billion

For earnings history and earnings-related data on CVS Health (CVS) click here.